ReNeuron Group plc
RENE.L · LSE
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £6 | £10 | £15 | £13 |
| + Debt | £0 | £1 | £1 | £1 |
| Enterprise Value | -£6 | -£9 | -£14 | -£11 |
| Revenue | £1 | £0 | £0 | £6 |
| % Growth | 31.5% | 56.8% | -95.8% | – |
| Gross Profit | £0 | £0 | -£9 | -£10 |
| % Margin | 49.6% | 19.6% | -3,597.7% | -169.3% |
| EBITDA | -£6 | -£11 | -£13 | -£13 |
| % Margin | -1,201.9% | -2,657.3% | -5,057.6% | -221% |
| Net Income | -£5 | -£10 | -£11 | -£11 |
| % Margin | -1,020.4% | -2,404.2% | -4,415.2% | -188.2% |
| EPS Diluted | -0.095 | -0.17 | -0.29 | -0.35 |
| % Growth | 44.3% | 41.4% | 17.1% | – |
| Operating Cash Flow | -£7 | -£7 | -£6 | -£14 |
| Capital Expenditures | -£0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£8 | -£8 | -£6 | -£14 |